Innovating Multispecific Design & Targeting to Expand the Therapeutic Window Between Efficacy & Toxicity to Achieve Clinical Success

The bispecific and multispecific antibody field is advancing rapidly, fuelled by strong clinical readouts, growing biopharma investment, and increasingly sophisticated antibody designs. As programmes evolve beyond first‑generation bispecifics toward trispecific and multispecific strategies, the industry is sharpening its focus on improving efficacy while expanding the therapeutic window through safer, more controllable designs.

Building on the Proven Success of the World Bispecific Summit US
The World Bispecific Summit Europe builds on the success of its US counterpart, bringing the same depth of technical focus, high‑calibre speaker faculty, and senior‑level scientific exchange to the European bispecific community.

Translation in solid tumours remains significantly more challenging than in haematology, with stromal barriers and immunosuppressive microenvironments limiting clinical efficacy.
➡️ Hear real‑world case studies from Molecular Partners, LabGenius, Accession Therapeutics, Biomunex, and more.

Improving translational predictivity
Particularly for immune‑modulating formats, where preclinical models often fail to reflect human immune activation or cytokine release risk.
➡️ Gain insights from Amgen and Pfizer on bridging this critical gap.

Expanding the therapeutic window
How do you balance potency with safety for T‑cell engagers and bispecific ADCs without compromising efficacy?
➡️ Learn how Genmab, AstraZeneca, NovalGen, and Biomunex are tackling this challenge.

Achieving true target & modality differentiation
Standing out in a crowded bispecific landscape requires more than incremental design changes.
➡️ Hear perspectives from Enara Bio, T‑Cypher Bio, DISCO Pharmaceuticals, and AstraZeneca on achieving meaningful differentiation.